`
`Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals MADISON, N.J., June 6, 2012 /PRNewswire/
`
`Bausch + Lomb Completes the Acquisition of ISTA
`Pharmaceuticals
`Transaction Broadens Bausch + Lomb's Pharmaceutical Portfolio and Enhances its Pipeline of LateStage Products
`
` ()
`
`
`
`
`
`
`
`
`
`
`
`MADISON, N.J., June 6, 2012 /PRNewswire/ Bausch + Lomb, the global eye health company, announced
`today that it has completed its acquisition of ISTA Pharmaceuticals, Inc., a leading pharmaceutical company.
`The addition of ISTA bolsters Bausch + Lomb's product portfolio and pipeline, increasing the company's
`therapeutic offerings for physicians and their patients and creating opportunity for future growth.
`
`"This combination is a big step for Bausch + Lomb and an exciting development for eye health. Together, we
`are building a highperformance company that can deliver even more benefits for the patients and customers
`we serve," said Brent Saunders, president and chief executive officer, Bausch + Lomb. "ISTA's business
`complements our own very well, and we are excited about the opportunities this transaction creates."
`
`ISTA's four prescription products, BROMDAY™, BEPREVE®, ISTALOL®, and VITRASE®, will complement
`Bausch + Lomb's existing prescription ophthalmology products, including Lotemax® and Besivance®, and
`branded OTC eye vitamins PreserVision® and Ocuvite®. Bausch + Lomb's pharmaceutical pipeline now has
`nearly double the number of midto latestage innovations. The newly combined pipeline includes
`PROLENSA™, TPRED™, BEPOMAX™ and BEPOSONE™, ISTA's candidates to treat ocular inflammation
`and pain and allergyrelated nasal conditions, and Bausch + Lomb's pharmaceutical innovations, including the
`first of a new class of ocular antiinflammatory agents as well as a promising approach to reducing intraocular
`pressure in patients with openangle glaucoma or ocular hypertension.
`
`"The addition of ISTA creates exciting new opportunities for Bausch + Lomb's rapidly growing pharmaceutical
`business," said Daniel M. Wechsler, executive vice president and president, Bausch + Lomb Global
`Pharmaceuticals. "ISTA is an exceptional company with strong formulation expertise, a robust portfolio of
`therapeutic offerings and a promising pipeline. And, importantly, our new colleagues from ISTA share our
`passion for innovation and delivering products that will help patients see better and improve the quality of their
`lives."
`
`http://www.prnewswire.com/newsreleases/bauschlombcompletestheacquisitionofistapharmaceuticals157534185.html
`
`1/2
`
`SENJU EXHIBIT 2210
`LUPIN v SENJU
`IPR2015-01105
`
`PAGE 1 OF 2
`
`
`
`10/27/2015
`
`Bausch + Lomb Completes the Acquisition of ISTA Pharmaceuticals MADISON, N.J., June 6, 2012 /PRNewswire/
`
`The allcash transaction with ISTA, valued at approximately $500 million, is expected to add more than $150
`million to Bausch + Lomb's annualized sales and be accretive to Bausch + Lomb's EBITDA this year.
`
`Bausch + Lomb is committed to ensuring its combination with ISTA is as seamless as possible for its
`customers, suppliers and other partners, and will be providing updates throughout the integration process. A
`list of frequently asked questions regarding today's news can be found at www.bausch.com
`(http://www.bausch.com/).
`About Bausch + Lomb
`Bausch + Lomb is one of the bestknown and most respected healthcare companies in the world. Its core
`businesses include contact lenses and lens care products, ophthalmic surgical devices and instruments, and
`ophthalmic pharmaceuticals. Founded in 1853, the company is headquartered in Rochester, N.Y., and
`employs more than 11,000 people worldwide. Its products are available in more than 100 countries. More
`information is available at www.bausch.com (http://www.bausch.com/).
`News Media Contacts:
`
`Teresa Panas
`Director, Global Pharmaceutical Communications
`+1 9733606382 or teresa.panas@bausch.com (mailto:teresa.panas@bausch.com)
`
`Adam Grossberg
`Vice President, Global Communications and Investor Relations
`+1 9733606439 or adam.grossberg@bausch.com (mailto:adam.grossberg@bausch.com)
`
`SOURCE Bausch + Lomb
`
`RELATED LINKS
`http://www.bausch.com (http://www.bausch.com)
`
`http://www.prnewswire.com/newsreleases/bauschlombcompletestheacquisitionofistapharmaceuticals157534185.html
`
`2/2
`
`PAGE 2 OF 2